Essential drugs for cancer therapy: A World Health Organization consultation

Annals of Oncology

Volumn 10, Issue 4, 1999, Pages 385-390

  Sikora, K ^a   Advani, S ^g   Koroltchouk, V ^a   Magrath, I ^b   Levy, L ^c   Pinedo, H ^d   Schwartsmann, G ^e   Tattersall, M ^g   Yan, S ^f  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

^e HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^f CANCER HOSPITAL   (China)

^g NONE

Author keywords

Chemotherapy; Drugs; Generics; Prioritization

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FLUTAMIDE; GENERIC DRUG; MEGESTROL ACETATE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; NAVELBINE; PACLITAXEL; PREDNISOLONE; PROCARBAZINE; TAMOXIFEN; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER INHIBITION; COST BENEFIT ANALYSIS; DRUG COST; GOVERNMENT; HEALTH CARE QUALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOLID TUMOR; WORLD HEALTH ORGANIZATION;

EID: 0032931825     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008367822016     Document Type: Article

References (29)

1. World Health Organization. National Cancer Control Programmes. Policies and Managerial Guidelines. Geneva: WHO 1995.
2. Sikora K. Developing a global strategy for cancer. Eur J Cancer 1999 (in press).
3. Stiller C. Centralised treatment, entry to trials and survival. Br J Cancer 1994; 70: 352-62.
4. World Health Organization. Essential Drugs for Cancer Chemotherapy: Memorandum From a WHO Meeting. Bulletin of the WHO 1985; 63: 999-1002.
5. WHO Consultation. Essential Drugs for Cancer Chemotherapy. Bulletin of the World Health Organization 1994; 72: 693-8.
6. Sobin LH, Fleming ID (eds). TNM Classification of Malignant Tumours, 5th edition. Geneva: UICC 1997.
7. Benjamin I, Glodwein JW, Rubin SC et al. Oncolink: A cancer information resources for oncologists and the public on the internet. Gynecol Oncol 1996; 60: 8-15.
8. Karjalainen S, Palva I. Do treatment protocols improve end results. BMJ 1989; 299: 1069-72.
9. Early Breast Trialist's Collaborative Group. Systematic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992; 339: 1-15.
10. Fuchs CS, Mayer RJ. Adjuvant chemotherapy for colon and rectal cancer. Semin Oncol 1995; 22: 472-87.
11. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
12. Piccart MJ, Bertelsen K, Stuart G et al. Is cisplatin-paclitaxel standard in first-line treatment of advancerd ovarian cancer? Proc Am Soc Clin Oncol 1997; 16: 3 (Abstr 1258).
13. McGuire W, Neugut A, Arikaian S et al. Analysis of the cost effectiveness of paclitaxel as an alternative combination therapy for advanced ovarian cancer. J Clin Oncol 1997; 15: 640-5.
14. Debruyne FM, Dijkman GA. Advances and trends in hormonal therapy for advanced prostate cancer. Eur Urol 1995; 28: 177-88.
15. Anonymous. Paclitaxel and docetaxel in breast and ovarian cancer. Drug Ther Bull 1997; 35: 43-6.
16. Rustin GJ, Nelstrop AE, Crawford M. Phase II trial of oral altretamine for relapsed ovarian carcinoma. J Clin Oncol 1997; 15: 172-6.
17. Creemers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer. J Clin Oncol 1996; 14: 3056-61.
18. Bunn PA. The emerging role of gemcitabine in lung cancer. Semin Oncol 1997; 24: S7-1.
19. Bertino JR. Irinotecan for colorectal cancer. Semin Oncol 1997; 24: S18-3.
20. Sikora K. Gene therapy in developing countries. Gene Ther 1998; 5:3-4.
21. Frei E, Cannellos GP. Dose, a critical factor in cancer chemotherapy. Am J Med 1986; 69: 585-9.
22. Waters TM. Economic analysis of new technologies: the case for stem cell therapy. J Clin Oncol 1997; 15: 2-4.
23. 3 receptor antagonists: Differences and similarities. Eur J Cancer 1997; 33: 1364-70.
24. Baldini E, Tibaldi C, Lencioni M et al. Filgrastim and lack of support of intensive adjuvant chemotherapy for high risk breast cancer patients. Am J Clin Oncol 1997; 20: 169-72.
25. World Health Organization. Symptom Relief in Terminal Illness. Geneva: WHO 1998.
26. World Helath Organization. Cancer Pain Relief: With a Guide to Opioid Availability. Geneva: WHO 1998.
27. Courtenay M, Butler M. Nurse prescribing - the knowledge base. Nurs Times 1998; 94: 40-2.
28. Esparza DM, Young N, Luongo JA. Effective planning for office and outpatient chemotherapy administration. Semin Oncol Nurs 1989; 5: 8-14.
29. Monographs. Integrating Economic Analysis into Cancer Clinical Trials - American Society of Clinical Oncology Economics Workbook. J Natl Cancer Inst 1998; 24.